Skip to main content
Erschienen in: Abdominal Radiology 3/2020

23.10.2019 | Hollow Organ GI

Role of 18F-FDG PET/CT in restaging and follow-up of patients with GIST

verfasst von: Domenico Albano, Bonacina Mattia, Raffaele Giubbini, Francesco Bertagna

Erschienen in: Abdominal Radiology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gastrointestinal stromal tumor (GIST) is a rare tumor with high risk of recurrence and poor prognosis in case of advanced GIST. The aim of this study was to evaluate the possible role of 18F-FDG PET/CT in restaging GIST.

Methods

Fifty-four patients (30 male) with histological proven GIST underwent 100 18F-FDG PET/CT for restaging in suspected recurrence or during follow-up. Histopathology results and/or clinical/imaging follow-up for at least 12 months were considered as reference standard. Moreover, the diagnostic accuracy and clinical impact of 18F-FDG PET/CT were calculated.

Results

Twenty-seven (27%) 18F-FDG PET/CT were positive, while the remaining 73 (73%) were negative. Sensitivity, specificity, PPV, NPV, and accuracy of PET/CT were 89% (95% CI 72–98%), 97% (95% CI 90–100%), 93% (95% CI 76–98%), 96% (95% CI 89–98%), and 95% (95% CI 89–98%). 18F-FDG PET/CT had a positive clinical impact in 18/100 studies changing the management, in 8 cases switching from local therapy to systemic therapy due to the detection of disseminate disease at PET/CT, in three cases recognizing relapse not detected by conventional imaging, and in 7 cases demonstrating to be true negative and avoiding unnecessary therapies.

Conclusions

18F-FDG PET/CT seems to be an accurate method for detection and localization of local and distant recurrence in GIST with good sensitivity and specificity and significant impact on clinical decision-making.
Literatur
1.
Zurück zum Zitat Soreide K, Sandvik OM, Soreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol 2016;40:39–46.CrossRef Soreide K, Sandvik OM, Soreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol 2016;40:39–46.CrossRef
2.
Zurück zum Zitat Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, et al. Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clin Cancer Res 2007; 13: 170–181.CrossRef Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, et al. Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clin Cancer Res 2007; 13: 170–181.CrossRef
3.
Zurück zum Zitat Joensuu H. Gastrointestinal stromal tumor (GIST). Annals of Oncology 2006; 17: 280–286.CrossRef Joensuu H. Gastrointestinal stromal tumor (GIST). Annals of Oncology 2006; 17: 280–286.CrossRef
4.
Zurück zum Zitat Miettinen M, Lasota J. Gastrointestinal stromal tumors — definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv 2001; 438: 1–12.CrossRef Miettinen M, Lasota J. Gastrointestinal stromal tumors — definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv 2001; 438: 1–12.CrossRef
5.
Zurück zum Zitat Yan BM, Kaplan GG, Urbanski S, Nash CL, Beck PL: Epidemiology of gastrointestinal stromal tumors in a defined Canadian Health Region: a population-based study. Int J Surg Pathol 2008; 16: 241–250.CrossRef Yan BM, Kaplan GG, Urbanski S, Nash CL, Beck PL: Epidemiology of gastrointestinal stromal tumors in a defined Canadian Health Region: a population-based study. Int J Surg Pathol 2008; 16: 241–250.CrossRef
6.
Zurück zum Zitat Jamali F, Darwiche S, El-Kinge N, Tawil A, Sowed A. Disease progression following Imatinib failure in gastrointestinal stromal tumors: Role of surgical therapy. The Oncologist 2007; 12: 438–442.CrossRef Jamali F, Darwiche S, El-Kinge N, Tawil A, Sowed A. Disease progression following Imatinib failure in gastrointestinal stromal tumors: Role of surgical therapy. The Oncologist 2007; 12: 438–442.CrossRef
7.
Zurück zum Zitat DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51–58.CrossRef DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51–58.CrossRef
8.
Zurück zum Zitat Parfitt J, Streutker C, Riddell R, Driman D. Gastrointestinal stromal tumors: A contemporary review. Pathology — Research and Practice 2006; 202: 837–847.CrossRef Parfitt J, Streutker C, Riddell R, Driman D. Gastrointestinal stromal tumors: A contemporary review. Pathology — Research and Practice 2006; 202: 837–847.CrossRef
9.
Zurück zum Zitat Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006; 32: 961–963.CrossRef Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006; 32: 961–963.CrossRef
10.
Zurück zum Zitat Barnes G, Bulusu VR, Hardwick RH, Carroll N, Hatcher H, Earl HM, et al. A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec). Int J Surg 2005; 3: 206–212.CrossRef Barnes G, Bulusu VR, Hardwick RH, Carroll N, Hatcher H, Earl HM, et al. A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec). Int J Surg 2005; 3: 206–212.CrossRef
11.
Zurück zum Zitat Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127–1134.CrossRef Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127–1134.CrossRef
12.
Zurück zum Zitat Ponsaing L, Hansen MB. Therapeutic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol 2007; 13: 3316–3322.CrossRef Ponsaing L, Hansen MB. Therapeutic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol 2007; 13: 3316–3322.CrossRef
13.
Zurück zum Zitat Scola D, Bahoura L, Copelan A, Shirkhoda A, Sokhandon F. Getting the GIST: a pictorial review of the various patterns of presentation of gastrointestinal stromal tumors on imaging. Abdom Radiol (NY) 2017;42:1350-64.CrossRef Scola D, Bahoura L, Copelan A, Shirkhoda A, Sokhandon F. Getting the GIST: a pictorial review of the various patterns of presentation of gastrointestinal stromal tumors on imaging. Abdom Radiol (NY) 2017;42:1350-64.CrossRef
14.
Zurück zum Zitat Vernuccio F, Taibbi A, Picone D, et al. Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response. Anticancer Res 2016;36:2639–48.PubMed Vernuccio F, Taibbi A, Picone D, et al. Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response. Anticancer Res 2016;36:2639–48.PubMed
15.
Zurück zum Zitat Albano D, Zizioli V, Treglia G, et al. Role of 18F-FDG PET/CT in restaging and follow-up of patients with uterine sarcomas. Rev Esp Med Nucl Imagen Mol. 2019;38:10–16PubMed Albano D, Zizioli V, Treglia G, et al. Role of 18F-FDG PET/CT in restaging and follow-up of patients with uterine sarcomas. Rev Esp Med Nucl Imagen Mol. 2019;38:10–16PubMed
16.
Zurück zum Zitat Albano D, Zizioli V, Odicino F, et al. Clinical and prognostic value of 18F-FDG PET/CT in recurrent endometrial carcinoma. Rev Esp Med Nucl Imagen Mol. 2019;38:87–93.CrossRef Albano D, Zizioli V, Odicino F, et al. Clinical and prognostic value of 18F-FDG PET/CT in recurrent endometrial carcinoma. Rev Esp Med Nucl Imagen Mol. 2019;38:87–93.CrossRef
17.
Zurück zum Zitat Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and Dual-Modality PET/CT Imaging for Monitoring of Imatinib (STI571) Therapy in Patients with Gastrointestinal Stromal Tumors. J Nucl Med 2004;45:357–365.PubMed Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and Dual-Modality PET/CT Imaging for Monitoring of Imatinib (STI571) Therapy in Patients with Gastrointestinal Stromal Tumors. J Nucl Med 2004;45:357–365.PubMed
18.
Zurück zum Zitat Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Can Netw 2010;8 Suppl 2:S1–41.CrossRef Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Can Netw 2010;8 Suppl 2:S1–41.CrossRef
19.
Zurück zum Zitat Bertagna F, Bosio G, Orlando E, Biasotto G, Giubbini R. Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST). Nucl Med Rev Cent East Eur. 2010;13:76–80.PubMed Bertagna F, Bosio G, Orlando E, Biasotto G, Giubbini R. Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST). Nucl Med Rev Cent East Eur. 2010;13:76–80.PubMed
20.
Zurück zum Zitat Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17–21.PubMed Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17–21.PubMed
21.
Zurück zum Zitat American Joint Committee on Cancer. Gastrointestinal Stromal Tumor. In: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017:523. American Joint Committee on Cancer. Gastrointestinal Stromal Tumor. In: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017:523.
22.
Zurück zum Zitat Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459–65.CrossRef Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459–65.CrossRef
23.
Zurück zum Zitat Ponsaing L, Hansen MB. Therapeutic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol 2007; 13:3316–3322.CrossRef Ponsaing L, Hansen MB. Therapeutic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol 2007; 13:3316–3322.CrossRef
24.
Zurück zum Zitat Miyake KK, Nakamoto Y, Mikami Y, Tanaka S, Higashi T, Tadamura E, et al. The predictive value of preoperative 18F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumour. Eur Radiol 2016;26:4664–4674.CrossRef Miyake KK, Nakamoto Y, Mikami Y, Tanaka S, Higashi T, Tadamura E, et al. The predictive value of preoperative 18F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumour. Eur Radiol 2016;26:4664–4674.CrossRef
25.
Zurück zum Zitat Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39:2012–20.CrossRef Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39:2012–20.CrossRef
26.
Zurück zum Zitat Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004;25:433–438.CrossRef Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004;25:433–438.CrossRef
27.
Zurück zum Zitat Yoshikawa K, Shimada M, Kurita N, Sato H, Iwata T, Morimoto S et al. The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors. Surg Today 2013; 43: 1162–1167.CrossRef Yoshikawa K, Shimada M, Kurita N, Sato H, Iwata T, Morimoto S et al. The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors. Surg Today 2013; 43: 1162–1167.CrossRef
28.
Zurück zum Zitat Park JW, Cho CH, Jeong DS, Chae HD. Role of F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST: predicting malignant potential pre-operatively. J Gastric Cancer. 2011;11:173–179.CrossRef Park JW, Cho CH, Jeong DS, Chae HD. Role of F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST: predicting malignant potential pre-operatively. J Gastric Cancer. 2011;11:173–179.CrossRef
29.
Zurück zum Zitat Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, et al. 18Ffluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005;29:1429–1435.CrossRef Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, et al. 18Ffluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005;29:1429–1435.CrossRef
30.
Zurück zum Zitat Yamada M, Niwa Y, Matsuura T, Miyahara R, Ohashi A, Maeda O, et al. Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy. Scand J Gastroenterol 2007;42:633–641.CrossRef Yamada M, Niwa Y, Matsuura T, Miyahara R, Ohashi A, Maeda O, et al. Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy. Scand J Gastroenterol 2007;42:633–641.CrossRef
31.
Zurück zum Zitat Cho MH, Park CK, Park M, Kim WK, Cho A, Kim H. Clinicopathologic Features and Molecular Characteristics of Glucose Metabolism Contributing to 18F-fluorodeoxyglucose Uptake in Gastrointestinal Stromal Tumors. Plos One 2015;10:e0141413.CrossRef Cho MH, Park CK, Park M, Kim WK, Cho A, Kim H. Clinicopathologic Features and Molecular Characteristics of Glucose Metabolism Contributing to 18F-fluorodeoxyglucose Uptake in Gastrointestinal Stromal Tumors. Plos One 2015;10:e0141413.CrossRef
32.
Zurück zum Zitat Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32:153–162.CrossRef Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32:153–162.CrossRef
33.
Zurück zum Zitat Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:439–45.CrossRef Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:439–45.CrossRef
34.
Zurück zum Zitat Kaneta T, Takahashi S, Fukuda H, Arisaka, Oriuchi N, Hayashi T, et al. Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study. Ann Nucl Med 2009;23:459–464.CrossRef Kaneta T, Takahashi S, Fukuda H, Arisaka, Oriuchi N, Hayashi T, et al. Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study. Ann Nucl Med 2009;23:459–464.CrossRef
Metadaten
Titel
Role of 18F-FDG PET/CT in restaging and follow-up of patients with GIST
verfasst von
Domenico Albano
Bonacina Mattia
Raffaele Giubbini
Francesco Bertagna
Publikationsdatum
23.10.2019
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 3/2020
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-02274-y

Weitere Artikel der Ausgabe 3/2020

Abdominal Radiology 3/2020 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.